Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤ 12.0%~* Patients with visual impairment due to DME in at least one eye~* BCVA ≥ 24 and ≤ 78 letters in the study eye~Exclusion Criteria:~* Active intraocular inflammation~* Any active infection in either eye at the~* Structural damage within 0.5 disc diameter of the center of the macula in the study eye~* Uncontrolled glaucoma in either eye at screening~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Discretion of the investigator (DI) (Type: EXPERIMENTAL): ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
- Pro re nata (PRN) (Type: ACTIVE_COMPARATOR): ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred

Based on this trial design, predict the completion outcome and termination type (if applicable).